SELLAS Life Sciences Group Overview
Get informed when a big investor buys or sells
+ Follow-45.81
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
As of the most recent data, SLS shows a P/E ratio of -45.81. That is below the Healthcare sector average of 70.94. Scroll down for historical charts and peer comparison views.
The Healthcare sector average P/E ratio is about 70.94. SELLAS Life Sciences Group is at -45.81, which is lower that average. That is roughly 164.6% below the sector mean. Use the comparison chart on this page to see how SLS stacks up against individual peers as well.
Investors watch SLS's P/E ratio because it compresses price and fundamentals into one number that is easy to compare across companies and over time. SELLAS Life Sciences Group's latest reading is -45.81. Combining that with growth, ROE, and debt metrics usually beats relying on a single multiple.
Besides this p/e ratio page, Stockcircle has SELLAS Life Sciences Group's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect P/E ratio (currently -45.81) with ownership activity and broader fundamentals.
The Healthcare average P/E ratio is about 70.94, while SLS is at -45.81. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.
